The MELOW (Midlife Empowerment and Longevity through Optimizing Wellness) study is a 12-month longitudinal research initiative evaluating a personalized wellness programme for midlife women with abdominal obesity. This study investigates the impact of integrated digital and biological monitoring on visceral adipose tissue, the management of menopausal symptoms, and the reduction of overall cardiometabolic risk.
By utilizing longitudinal physiological assessments and advanced wearable technology, the research aims to establish evidence-based strategies for enhancing healthy longevity and metabolic resilience during the menopausal transition.
What will I need to do?
- Attend three in-person clinic visits for clinical measurements and blood sampling (Baseline, 6 months, and 12 months).
- Complete online questionnaires at Baseline, 6 months, and 12 months.
- Utilize Continuous Glucose Monitoring (CGM) for a period of 15 days.
- Wear a smart ring for 12 months to monitor physiological data.
- Regularly engage with a dedicated research application for the duration of the study.
Eligibility
- Women aged 21–65 years old.
- Report mild climacteric symptoms (MRS score ≥ 5).
- Waist Circumference ≥ 80 cm.
- Possess a personal mobile device compatible with CGM and smart ring technology.
Benefits
- Receive a comprehensive health screening and blood results.
- Obtain a detailed body composition analysis.
- Gain personalized access to your metabolic and physiological health data via wearable technology.
Important to know
- Exclusion criteria include: Use of HRT or contraceptives, severe psychiatric illness, participation in concurrent clinical trials, or uncontrolled chronic conditions.
- Participants must be able to understand and communicate in English.